introduct
adjuv
form
integr
compon
inactiv
subunit
vaccin
formul
care
proper
select
adjuv
help
promot
appropri
immun
respons
target
pathogen
innat
adapt
level
protect
immun
elicit
area
cover
herein
describ
recent
progress
understand
mode
action
adjuv
licens
use
human
vaccin
clinic
preclin
stage
innat
adapt
level
differ
pathogen
distinct
characterist
requir
host
mount
appropri
immun
respons
adjuv
select
elicit
tailormad
immun
respons
specif
pathogen
base
uniqu
properti
identif
biomark
adjuvant
sever
candid
vaccin
use
omicsbas
technolog
unravel
mechan
action
modern
experiment
adjuv
expert
opinion
adjuv
technolog
revolution
last
two
decad
indepth
understand
role
adjuv
activ
innat
immun
system
combin
system
vaccinolog
approach
led
develop
nextgener
novel
adjuv
use
vaccin
challeng
pathogen
specif
target
popul
articl
histori
develop
vaccin
infecti
diseas
one
remark
accomplish
histori
mankind
smallpox
erad
world
diseas
like
diphtheria
poliomyel
pertussi
measl
neonat
tetanu
significantli
control
vaccin
live
attenu
vaccin
immunogen
chanc
live
virusinduc
diseas
progress
popul
underdevelop
compromis
immun
system
contrast
inactiv
viru
vaccin
safe
unsuit
natur
infect
pathogen
fail
induc
longterm
immun
recombin
subunit
vaccin
consid
one
attract
modern
vaccin
type
due
high
safeti
profil
howev
subunit
vaccin
inher
immunogen
overcom
limit
adjuv
incorpor
subunit
vaccin
enhanc
immunogen
vaccin
antigen
adjuv
facilit
develop
vaccin
target
pathogen
live
attenu
inactiv
vaccin
ineffect
undesir
identif
select
new
adjuv
thu
critic
also
challeng
success
subunit
vaccin
develop
fact
adjuv
approv
use
human
vaccin
till
year
ago
least
partial
attribut
dearth
knowledg
mechan
action
adjuv
howev
present
six
adjuv
alum
cpg
odn
approv
use
human
vaccin
possibl
structur
character
sever
adjuv
identif
variou
pattern
recognit
receptor
prr
costimulatori
ligand
receptor
enabl
us
better
understand
mode
action
adjuv
molecular
level
understand
mode
action
adjuv
critic
design
vaccin
elicit
pathogenspecif
effector
longterm
memori
respons
assess
adjuv
safeti
development
regulatori
stage
possibl
mechan
action
adjuv
exert
adjuvant
discuss
subsequ
section
repres
schemat
figur
adjuv
deliveri
system
subunit
vaccin
liposom
immun
stimul
complex
iscom
nanoparticl
consid
effect
stimul
protect
immun
adjuv
prevent
rapid
degrad
protein
peptid
vivo
therebi
enhanc
dose
effect
vaccin
antigen
liposom
use
vaccin
formul
influenza
chlamydia
malaria
tuberculosi
tb
coadministr
antigen
cation
liposom
lead
induct
stronger
antigenspecif
immun
respons
neutral
anion
liposom
liposom
effect
vaccin
deliveri
system
act
carrier
adjuv
liposomebas
formul
consist
monophosphoryl
lipid
mpla
improv
saponinbas
tensoact
adjuv
iscom
iscomatrix
matrixm
tm
particul
antigen
deliveri
system
power
immunostimul
activ
iscom
saponin
cholesterol
phospholipid
form
cagelik
structur
nm
diamet
adjuv
iscomatrix
structur
similar
structur
without
incorpor
antigen
antigen
formul
iscomatrix
prepar
iscomatrix
vaccin
antigen
deliveri
immunostimulatori
properti
present
iscomatrix
within
first
hour
inject
antigeniscomatrix
complex
traffic
drain
lymph
node
dln
antigen
deliveri
take
place
uptak
resid
dendrit
cell
dc
antigen
present
cell
apc
iscom
current
use
develop
influenza
vaccin
iscomatrix
hepat
c
viru
hcv
influenza
candid
cancer
vaccin
human
matrixm
tm
adjuv
evalu
vaccin
influenza
herp
simplex
viru
hsv
type
malaria
nanoparticl
polymer
colloid
carrier
antigen
enabl
sitedirect
deliveri
prolong
releas
antigen
facilit
altern
mode
vaccin
administr
inhal
optic
topic
deliveri
exampl
polymer
nanoparticl
poli
lacticcoglycol
acid
plga
poli
lactic
acid
pla
poli
glycol
acid
pga
poli
hydroxybutyr
phb
chitosan
aluminum
salt
also
use
deliveri
system
crystal
alum
bind
alter
lipid
dc
plasma
membran
trigger
cell
activ
facilit
deliveri
antigen
without
alum
intern
dc
aluminum
salt
use
adjuv
human
vaccin
diphtheria
tetanu
pertussi
rabi
anthrax
hepat
b
vitro
studi
reveal
oilinwat
emuls
adjuv
increas
phagocytosi
pinocytosi
indirectli
promot
better
antigen
uptak
apc
instead
directli
target
dc
antigen
uptak
act
upstream
promot
influx
dc
precursor
cell
augment
differenti
dc
safeti
demonstr
variou
clinic
studi
antigen
hepat
b
viru
hbv
hcv
cytomegaloviru
cmv
hsv
human
immunodefici
viru
hiv
similar
directli
activ
dc
vitro
intramuscular
inject
mice
promot
influx
monocyt
dc
granulocyt
dln
articl
highlight
identif
new
prr
agonist
expect
lead
identif
adjuv
particular
prr
agonist
combin
adjuv
hold
great
promis
system
vaccinolog
provid
better
understand
mode
action
adjuv
allow
identif
uniqu
biomark
adjuvant
mani
pathogen
hostpathogen
interact
character
detail
knowledg
hostpathogen
interact
combin
mechan
action
adjuv
lead
use
specif
adjuv
vaccin
distinct
pathogen
figur
schemat
represent
highlight
possibl
mechan
action
adjuv
exert
adjuvant
adjuv
serv
depot
mediat
recruit
apc
act
deliveri
system
facilit
uptak
antigen
apc
adjuv
may
activ
innat
immun
respons
signal
cell
surfac
clr
mincl
cytosol
nlr
cell
surfac
tlr
endosom
tlr
cytosol
rigi
signal
via
prr
may
lead
activ
sever
transcript
factor
result
product
proinflammatori
cytokin
chemokin
type
ifn
secret
chemokin
due
adjuv
may
also
result
recruit
infiltr
immun
cell
adjuv
activ
cga
particip
stingmedi
ifn
pathway
adjuv
enhanc
express
mhc
costimulatori
molecul
mediat
effici
present
antigen
cell
depend
upon
class
adjuv
cellular
andor
humor
immun
respons
may
induc
adjuv
also
play
import
role
gc
reaction
affin
matur
longliv
memori
respons
part
humor
immun
also
respons
enhanc
antigen
uptak
monocyt
particular
antigen
present
dln
process
mediat
presenc
safeti
squalenebas
adjuv
demonstr
toxicolog
studi
anim
model
well
phase
iiii
studi
human
depot
effect
refer
slow
prolong
antigen
releas
site
inject
provid
continu
stimul
immun
system
facilit
enhanc
antigen
uptak
apc
correl
induct
high
antibodi
titer
adjuvant
alum
origin
thought
due
depot
effect
howev
accord
recent
evid
depot
effect
mechan
exert
adjuv
activ
mous
model
alum
found
rapidli
induc
inflammatori
environ
via
induct
inflammatori
chemokin
turn
trigger
neutrophil
recruit
swarm
inject
site
furthermor
alum
induc
neutrophil
death
result
releas
extracellular
dna
strand
neutrophil
extracellular
trap
net
play
signific
role
adjuv
action
alum
oilin
water
emuls
waterinoil
emuls
cation
adjuv
formul
caf
cation
liposom
consist
combin
ddatdb
well
biodegrad
microand
nanoparticl
exhibit
adjuv
activ
via
depot
effect
mice
cation
liposom
exhibit
long
depot
effect
site
inject
strong
electrostat
interact
apc
contrast
adjuv
iscom
requir
depot
format
exert
adjuv
activ
rather
antigen
adjuv
clear
rapidli
site
administr
biodistribut
studi
mice
conduct
radiolabel
compon
reveal
constitu
infiltr
dln
within
min
inject
constitu
clear
inject
site
day
post
inject
suggest
dissoci
similarli
intramuscular
inject
vaccin
mice
indic
rapid
clearanc
antigen
inject
site
dln
differenti
biodistribut
dynam
pharmacokinet
antigen
suggest
vaccin
antigen
physic
associ
similarli
matrix
adjuv
formul
consist
nanoparticl
compris
saponin
cholesterol
phospholipid
physic
associ
matrix
antigen
requir
potent
immun
stimul
contrast
electrostat
interact
antigen
adjuv
requir
optim
adjuv
activ
similarli
optim
adjuvant
virosom
achiev
antigen
interest
associ
virosom
either
encapsul
attach
bilay
via
hydrophob
interact
success
yellow
fever
vaccin
live
attenu
viru
vaccin
attribut
abil
activ
multipl
tlr
includ
dc
mice
also
activ
human
monocytederiv
dc
plasmacytoid
dc
pdc
complex
activ
lipopeptid
analog
pam
csk
complex
activ
macrophag
activ
mycoplasma
poli
c
ligand
endosom
cytosol
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
protein
poli
c
two
deriv
polyi
c
u
ampligen
poli
ic
lc
hiltonol
use
clinic
trial
tumor
infecti
diseas
hiv
target
monophosphoryl
lipid
mpl
contain
mpl
approv
use
hbv
fendrix
human
papilloma
viru
hpv
vaccin
cervarix
contain
mpl
also
use
malaria
vaccin
rt
varicella
zoster
viru
vaccin
hzsu
found
efficaci
phase
iii
trial
recogn
bacteri
flagellin
signal
dc
play
import
role
intestin
iga
product
differenti
lead
strong
nuclear
factor
nf
activ
type
immun
respons
mice
contrast
flagellin
act
factor
cell
human
neonat
adult
recogn
singlestrand
rna
ssrna
molecul
target
smallmolecul
immun
potenti
smip
base
adjuv
imiquimod
resiquimod
use
hpv
viruslik
particl
vlp
vaccin
signal
induc
b
cellmedi
product
immunoglobulin
ig
interleukin
il
natur
killer
nk
cellmedi
product
signal
induc
cell
prolifer
product
memori
cell
activ
recogn
unmethyl
cpg
motifcontain
microbi
dna
immunostimulatori
sequenc
iss
agonist
use
hbv
vaccin
promot
higher
level
protect
antibodi
consequ
fewer
immun
lower
antigen
dose
need
mice
signal
lead
type
proinflammatori
respons
upregul
major
histocompat
complex
mhc
costimulatori
molecul
increas
cell
respons
b
cell
activ
respons
induct
humor
immun
antibodi
class
switch
intracellular
nlr
receptor
recogn
diaminopimelat
acid
dap
contain
muropeptid
gramneg
bacteria
detect
muramyl
dipeptid
mdp
compon
present
bacteri
peptidoglycan
adjuvant
mucos
adjuv
cholera
toxin
ct
mediat
receptor
adjuv
induc
damageassoci
molecular
pattern
damp
trigger
innat
immun
respons
vivo
damag
host
cell
therebi
result
releas
damp
factor
ex
rna
dna
subsequ
activ
innat
immun
receptor
cytosol
receptor
recogn
adjuv
quila
chitosan
well
atp
mdp
uric
acid
crystal
silica
compound
gener
damp
signal
reactiv
oxygen
speci
ro
induc
potassium
efflux
activ
alum
adjuvant
mice
also
attribut
activ
nacht
via
swell
ruptur
phagolysosom
releas
cathepsin
b
cytosol
subsequ
activ
caspas
releas
leucinerich
repeat
lrr
pyrinpaaddapin
domain
pyd
domainscontain
protein
inflammasom
releas
uric
acid
activ
stimul
interferon
ifn
gene
sting
ifn
regulatori
factor
irf
pathway
due
releas
dna
howev
valid
hypothes
human
warrant
ex
direct
role
adjuvant
alum
human
debat
instanc
gener
conclud
inflammasom
caspas
sometim
alway
requir
induct
cellassoci
antibodi
respons
respons
aluminum
salt
vivo
activ
vitro
howev
role
observ
vivo
formul
liposom
activ
human
dc
promot
cholesteroldepend
endocytosi
subsequ
lysosom
destabil
syk
activ
similar
alum
mice
endocin
lipid
adjuv
caus
cellular
damag
gener
damp
lactat
dehydrogenas
ldh
dna
rna
chitosan
induc
releas
mitochondri
dna
cytoplasm
activ
inflammasom
mice
aluminum
hydroxid
calcium
phosphat
adjuv
induc
releas
extracellular
atp
muscl
mice
act
danger
signal
damp
adjuv
bcd
induc
local
cellular
stress
death
result
releas
host
cellular
dna
serv
damp
induc
immun
respons
cytosol
dsdna
sens
sever
prr
absent
well
protein
cyclic
guanosin
monophosphateadenosin
monophosph
cgamp
synthas
cga
simultan
lead
activ
stingdepend
pathway
pathway
sting
bind
cyclic
dinucleotid
cdn
cyclic
digmp
cdg
cyclic
diamp
cda
mice
cdg
appear
safer
mucos
adjuv
cholera
toxin
promot
protect
immun
influenza
staphylococcu
streptococcu
klebsiella
infect
mice
chitosan
trigger
releas
intracellular
dna
result
engag
cgasst
pathway
dc
induc
type
ifn
product
isg
therebi
promot
robust
immun
lead
upregul
costimulatori
immun
marker
subsequ
activ
dc
well
induct
cellmedi
immun
cmi
carbohydratebas
adjuv
includ
glucan
fructan
mannan
chitinchitosan
carbohydr
compound
deriv
mycobacterium
spp
includ
lipoarabinomannan
muramyldipeptidemdp
well
lp
saponin
compound
includ
saponin
oilinwat
emuls
human
monocytederiv
dc
modc
also
compon
endocytos
via
action
membran
cholesterol
subsequ
lysosom
destabil
syk
activ
promot
proinflammatori
transcript
program
addit
cathepsin
b
lysosom
cystein
proteas
requir
activ
modc
vitro
also
requir
adjuv
activ
vivo
anoth
studi
lnresid
macrophag
play
key
role
adjuv
activ
upon
intramuscular
inject
mice
lead
rapid
induct
local
innat
immun
respons
dln
colocalis
lnresid
macrophag
crucial
innat
effector
respons
antigen
formul
via
caspas
inflammasom
activ
primari
mechan
action
carbohydratebas
adjuv
involv
interact
prr
tlr
ctype
lectin
receptor
clr
mincl
monocyt
apc
interact
activ
induc
inflammatori
chemokin
cytokin
respons
carbohydr
adjuv
also
activ
complement
pathway
gener
complement
compon
act
opsonin
chemokin
import
mechan
action
carbohydratebas
adjuv
includ
chemotaxi
lymphocyt
inflammasom
activ
eg
zymosan
mannan
poreform
facilit
antigen
entri
apc
via
interact
cholesterol
plasma
membran
eg
adjuv
induc
seri
signal
transduct
pathway
exert
action
innat
adapt
level
intramuscular
inject
mpl
mice
respons
activ
muscl
local
dln
synthet
deriv
mpl
induc
activ
select
activ
mapk
pathway
strongli
associ
optim
induct
protein
mice
inject
vaccin
promot
releas
lnresid
nk
cell
cell
pathway
enrich
analysi
differenti
express
gene
inject
sitedln
reveal
ifnsign
pathway
enrich
h
antiinflammatori
pathway
also
trigger
h
postinject
increas
level
detect
earli
serum
dln
human
macaqu
vaccin
vaccin
respect
cellular
molecular
synergi
mpl
use
combin
respons
earli
respons
turn
enhanc
immunogen
vaccin
adjuv
activ
janu
kinas
jak
signal
transduc
activ
transcript
stat
phosphoinositid
mapk
pathway
therebi
promot
bcell
tcell
differenti
via
sustain
activ
differenti
subtl
chemic
alter
mpla
made
develop
design
smipbas
known
sla
induc
trif
signal
produc
cytokin
chemokin
like
ifn
less
sla
oilinwat
emuls
slase
produc
capit
knowledg
combin
ifn
caspasedepend
inflammasom
signal
lead
power
adjuv
action
activ
pathway
well
jnk
mapk
pathway
program
dc
produc
induc
respons
extracellular
signalregul
kinas
erk
cfo
mapk
pathway
favor
respons
erkretinaldehyd
dehydrogenas
raldh
enzym
program
dc
induc
regulatori
treg
respons
similarli
complet
freund
adjuv
cfa
induc
transcript
mhcii
b
cell
activ
marker
via
calcineurinnuclear
factor
activ
tcell
nfat
rasmekerk
signal
pathway
saponin
adjuvant
reli
receptorsign
pathway
chitosan
engag
cgasst
pathway
induc
respons
mice
intact
signal
three
type
apc
dc
macrophag
b
cell
essenti
robust
activ
tlr
ligandbas
vaccin
adjuv
porb
ligand
cpg
ligand
induct
vivo
cytokin
respons
germin
center
gc
format
antibodi
product
base
microarray
analysi
mosca
et
al
demonstr
three
potent
human
vaccin
adjuv
cpg
odn
alum
modul
common
set
gene
adjuv
core
respons
gene
encod
cytokin
chemokin
innat
immun
receptor
ifninduc
protein
adhes
molecul
mous
muscl
establish
local
immunocompet
environ
due
nonpathogen
inflammatori
respons
associ
vaccin
adjuvant
compar
cpg
odn
alum
found
stronger
induc
adjuv
core
respons
gene
reflect
enhanc
rapid
influx
mhcii
cell
inject
site
effici
transport
antigen
dln
alum
induc
chemokin
involv
cellular
influx
presenc
promot
induct
leukocyterecruit
chemokin
neutrophilmobilis
cytokin
granulocyt
colonystimul
factor
proinflammatori
cytokin
chemokin
mice
agreement
increas
recruit
granulocyt
antigenload
monocyt
dln
aluminum
adjuv
facilit
recruit
differenti
inflammatori
monocyt
int
lyg
inflammatori
dc
therebi
enhanc
humor
cellular
immun
mani
result
alum
confirm
nonhuman
primat
exampl
vaccin
hiv
vaccin
adjuv
alum
trigger
recruit
monocyt
dc
neutrophil
muscl
subcutan
administr
iscomatrix
sheep
induc
rapid
transient
product
cytokin
influx
innat
cell
nk
cell
nkt
cell
neutrophil
migratori
dc
dc
dln
combin
adjuv
consist
poli
c
host
defens
peptid
pcep
deliv
intranas
transient
induc
product
chemokin
cytokin
murin
respiratori
tissu
promot
infiltr
activ
dc
macrophag
neutrophil
gener
improv
mucos
system
immun
respons
improv
qualiti
antibodi
respons
innat
immun
respons
play
profound
role
regul
magnitud
qualiti
persist
antibodi
respons
magnitud
antibodi
respons
critic
confer
protect
diphtheria
hepat
lyme
diseas
tetanu
yellow
fever
polio
rabi
pneumococc
infect
rsv
meningococc
infect
magnitud
qualiti
antibodi
cellmedi
respons
import
adjuv
system
use
malaria
rt
herp
zoster
hzsu
tb
hiv
vaccin
use
sever
influenza
vaccin
trival
inactiv
influenza
prepandem
influenza
candid
pandem
influenza
vaccin
use
licens
hbv
vaccin
adjuv
system
known
augment
antigenspecif
cell
antibodi
respons
murin
studi
er
stressrel
pathway
found
potenti
contribut
adjuvant
vivo
furthermor
express
er
stress
sensor
kinas
myeloid
cell
involv
adjuv
activ
er
stressrel
pathway
requir
induct
robust
tfh
respons
antigenspecif
antibodi
affin
matur
play
crucial
role
differenti
tfh
cell
well
express
tfh
cell
product
antibodi
alumadjuv
vaccin
act
produc
cell
facilit
optim
prime
clonal
expans
antibodi
product
antigenspecif
b
cell
mice
b
cell
tlr
ligand
adjuv
induc
upregul
surfac
marker
involv
antigen
uptak
mhci
mhcii
surfac
marker
involv
crosstalk
cell
ultim
lead
increas
antigenspecif
antibodi
product
howev
use
adjuv
hbv
hpv
vaccin
instead
aluminum
salt
higher
level
antibodi
induc
human
indic
ad
benefit
mpl
agonist
human
oilinwat
adjuv
similar
boost
innat
respons
increas
number
cell
requir
robust
antibodi
respons
support
induct
follicular
helper
tfh
cell
gc
respons
vaccin
unknown
mechan
human
promot
earli
inflamm
similar
result
anim
studi
type
ifn
respons
induc
children
earli
day
postimmun
influenza
vaccin
children
immun
nonadjuv
vaccin
type
ifn
respons
weaker
delay
earli
innat
immun
respons
reflect
induct
antigenspecif
tfh
cell
day
postvaccin
enhanc
antibodi
respons
human
immun
influenza
vaccin
b
induct
gc
reaction
promot
memori
b
cell
develop
immunolog
memori
distinct
hallmark
adapt
immun
system
contribut
protect
immun
infecti
diseas
gc
reaction
central
memori
develop
induct
certain
key
molecul
induc
tcell
costimul
ico
program
deathligand
bcell
lymphoma
protein
play
critic
role
regul
gc
differenti
affin
matur
longliv
memori
respons
tlr
express
gc
b
cell
follicular
dc
fdc
cell
profound
effect
induct
antibodi
respons
nanoparticl
resembl
virion
size
contain
tlr
ligand
mpl
combin
hemagglutinin
mediat
increas
persist
gc
significantli
influenc
differenti
memori
b
cell
critic
longliv
antibodi
respons
mice
subset
cell
ico
cell
associ
protect
antibodi
respons
confer
trival
splitviru
influenza
vaccin
effici
induc
memori
b
cell
differenti
plasma
cell
novel
adjuv
may
enhanc
bcell
activ
gc
bonemarrow
plasma
cell
surviv
exampl
heatlabil
enterotoxin
lt
escherichia
coli
administ
parenter
neonat
mice
facilit
matur
follicular
dc
gener
gc
induct
cellular
immun
effector
memori
cell
respons
signal
via
promot
immun
signal
via
promot
immun
dc
local
margin
zone
ln
induc
respons
well
exhibit
crosspresent
antigen
vivo
ex
vivo
mice
human
dc
equival
murin
respect
involv
crosspresent
extracellular
antigen
result
enhanc
mhci
express
type
ifn
product
poli
c
promot
antigen
crosspresent
cell
antigenspecif
ctl
contrast
alum
promot
respons
strong
antigenspecif
ige
induc
cell
immun
even
inhibit
immun
respons
mice
howev
alum
present
combin
mpla
respons
gener
found
unclear
whether
aluminum
saltinduc
bia
exist
human
rather
poor
cell
respons
induc
aluminum
salt
human
possibl
due
poor
stimul
innat
immun
system
squalenebas
oil
emuls
potent
induc
immun
well
toler
adjuv
cfa
preferenti
induc
mix
immun
respons
experiment
caf
combin
immunostimul
tdb
tb
vaccin
stimul
cellular
humor
immun
respons
well
promot
effici
polyfunct
memori
cell
immun
respons
mice
stingactiv
adjuv
cdn
formul
subunit
vaccin
deliv
intranas
promot
robust
immun
respons
correl
longlast
enhanc
protect
mycobacterium
tuberculosi
mice
adjuv
vaccin
promot
respons
may
protect
intracellular
pathogen
recruit
protect
cell
earlier
infect
neonat
cell
polar
toward
respons
reduc
respons
howev
novel
adjuv
induc
adultlik
respons
newborn
mice
cdg
mucos
adjuv
induc
immun
respons
mice
predominantli
induc
cell
respons
consist
dda
tdb
poli
c
induc
cell
respons
replac
rt
candid
malaria
vaccin
improv
antibodi
cell
respons
well
protect
efficaci
demonstr
random
doubleblind
phase
trial
activ
murin
subcapsular
macrophag
produc
promot
gener
cell
activ
apc
also
produc
promot
gener
tfh
cell
turn
favor
product
highavid
antibodi
b
cell
mice
human
intramuscular
inject
mice
induc
earli
product
lnresid
nk
cell
mediat
synergist
action
promot
respons
earli
product
nk
cell
prerequisit
optim
activ
dc
induct
antigenspecif
respons
antigen
respons
also
observ
ln
macaqu
inject
elev
level
serum
day
postimmun
increas
number
cytokineproduc
antigenspecif
cell
also
observ
human
immun
rt
malaria
vaccin
mechan
action
differ
adjuv
summar
tabl
adjuv
licens
use
human
vaccin
list
tabl
adjuv
clinic
trial
list
tabl
select
adjuv
base
mechan
action
distinct
type
pathogen
mucos
surfac
attract
target
pathogen
whose
port
entri
gastrointestin
eg
polio
viru
escherichia
salmonella
shigella
vibrio
helicobact
respiratori
influenza
viru
tuberculosi
mtb
adenoviru
coronaviru
rhinoviru
rsv
urogenit
tract
hsv
hpv
chlamydia
neisseria
mucos
adjuv
categor
toxinbas
lt
ct
immunostimulatori
mpl
cpg
deliveri
system
iscom
two
commonli
use
oral
toxinbas
adjuv
potent
also
toxic
use
mucos
adjuv
protect
efficaci
attain
intranas
vaccin
contain
mutant
lt
adjuv
use
hsv
bordetella
pertussi
streptococcu
pneumonia
natur
infect
rsv
induc
poor
antibodi
respons
impair
effector
function
perturb
local
persist
effector
memori
cell
induct
potent
local
mucos
immun
respons
requir
prevent
infect
high
system
antibodi
respons
also
requir
interrupt
diseas
progress
nanoemuls
safe
intranas
deliveri
induc
respons
mice
signific
inflamm
sastri
et
al
test
multipl
adjuv
sigma
adjuv
system
sa
oilinwat
adjuv
carbopol
alum
adjuplex
poli
c
poli
ic
lc
mpla
addavax
montanid
isa
found
adjuvantmedi
increas
rsvspecif
neutral
antibodi
respons
contextdepend
ie
whether
preexist
immun
present
speciesspecif
ie
mice
vs
calv
formul
rsv
fusion
f
protein
combin
adjuv
triadj
elicit
protect
mucos
system
immun
respons
rsv
mice
cotton
rat
mucos
epitheli
barrier
limit
bioavail
vaccin
antigen
sampl
apc
adjuv
polyethyleneimin
chitosan
use
penetr
enhanc
immunostimul
augment
bind
mucos
surfac
activ
innat
immun
mous
model
chitosan
polymer
nanoparticl
stimul
nasalassoci
lymphoid
tissu
nalt
produc
mucos
secretori
iga
igg
proinflammatori
cytokin
chemokin
also
act
mucos
adjuv
proinflammatori
cytokin
induc
mucos
ctl
antigenspecif
iga
similarli
chemokin
enhanc
mucos
iga
ctl
respons
neutral
antibodi
may
protect
acut
selflimit
mucos
pathogen
highli
invas
pathogen
caus
chronic
infect
hiv
hcv
herpesvirus
mycobacteria
mucos
innat
adapt
immun
respons
includ
ctl
well
secretori
iga
neutral
antibodi
port
pathogen
entri
requir
effect
optim
protect
mucos
adjuvantcontain
vaccin
elicit
local
system
immun
respons
effect
local
well
distant
site
control
enteropathogen
oral
administ
vaccin
must
overcom
challeng
antigen
degrad
immun
toler
biodegrad
microor
nanoparticl
requir
resist
low
ph
target
antigen
cell
bacteri
proteas
inhibitor
brucella
abortu
oral
adjuv
suitabl
subunit
vaccin
formul
inhibit
stomach
gut
proteas
delay
antigen
digest
lysosom
enhanc
antigen
present
recruit
immun
cell
gastrointestin
mucosa
intranas
immun
mice
polyi
c
u
ampligen
influenza
vaccin
promot
increas
level
protect
mucos
iga
system
igg
howev
mucos
vaccin
licens
human
primarili
due
dearth
safe
effect
mucos
adjuv
although
last
decad
constant
develop
new
effect
mucos
adjuv
toxic
exampl
intranas
inject
trigger
transient
facial
nerv
paralysi
bell
palsi
thu
urgent
need
address
safeti
issu
mucos
adjuv
phase
iii
trial
polyi
c
u
ampligen
demonstr
safe
random
phase
iii
trial
conduct
determin
safeti
efficaci
ampligen
patient
stage
iiiv
human
epiderm
growth
factor
receptor
posit
breast
cancer
result
trial
give
import
insight
applic
ampligen
therapeut
cancer
vaccin
pathogen
fungi
protozoan
parasit
complex
life
cycl
switch
among
sever
differ
form
life
histoplasma
capsulatum
grow
mold
soil
low
temperatur
upon
inhal
lung
switch
yeast
form
caus
histoplasmosi
interact
infect
macrophag
cell
lead
increas
product
cytokin
critic
import
gener
protect
immun
h
capsulatum
infect
mice
leukotrien
lipid
mediat
deriv
arachidon
acid
metabol
found
potent
adjuv
fungal
infect
malaria
vaccin
develop
imped
complex
life
cycl
plasmodium
spp
intracellular
stage
life
cycl
larg
physic
size
surfac
antigen
divers
enorm
genet
genom
plastic
parasit
replic
intracellularli
thu
partial
protect
immun
recognit
also
sequest
innat
immun
ligand
away
prr
sporozoit
gametocyt
stage
life
cycl
malaria
vaccin
need
establish
humor
immun
prevent
merozoit
enter
erythrocyt
liver
destroy
merozoit
opson
cmi
rt
mosquirix
malaria
candid
vaccin
target
infecti
sporozoit
stage
design
enhanc
antigenspecif
humor
cellular
immun
effector
cell
essenti
target
asexu
blood
stage
eventu
control
andor
clearanc
parasit
requir
antibodymedi
respons
mpl
two
compon
use
import
function
mpl
agonist
induc
product
cell
antibodi
isotyp
switch
mice
induc
neutral
antibodi
cytotox
cell
respons
requir
synergist
activ
mpl
optim
adjuv
activ
combin
plasmodium
antigen
induc
rapid
transient
innat
immun
respons
inject
site
dln
activ
immun
cell
includ
apc
well
gener
higher
antibodi
titer
compar
natur
exposur
howev
larg
phase
iii
trial
children
young
infant
seven
subsaharan
african
countri
although
rt
prevent
consider
number
case
clinic
malaria
infant
young
children
year
vaccin
efficaci
declin
subsequ
followup
infant
provid
signific
protect
sever
malaria
nonetheless
rt
play
signific
role
control
malaria
area
high
transmiss
use
conjunct
effect
prevent
measur
rt
clinic
trial
partnership
poli
c
deriv
great
import
vaccin
need
induc
immun
respons
variou
virus
pathogen
includ
p
falciparum
pam
csk
use
malaria
vaccin
contain
p
falciparum
circumsporozoit
protein
b
cell
epitop
univers
cell
epitop
result
induct
high
titer
antigenspecif
immun
volunt
herpesvirus
larg
virus
complex
genom
primari
infect
varicella
zoster
viru
vzv
caus
varicella
chickenpox
may
go
latent
phase
human
cranial
dorsal
root
ganglia
age
immun
dampen
result
declin
vzvspecif
cmi
may
induc
reactiv
viru
caus
shingl
henc
cmi
necessari
prevent
reactiv
latent
viru
vzv
vaccin
hzsu
shingrix
compos
vzv
glycoprotein
e
subunit
ge
antigen
b
recent
approv
prevent
herp
zoster
adult
age
year
older
select
adjuv
vzv
vaccin
compar
adjuv
system
induc
higher
number
secret
cell
thu
improv
cell
well
antibodi
respons
accept
clinic
safeti
profil
hpv
effect
evad
innat
immun
inhibit
ifn
receptor
signal
pathway
activ
isg
via
protein
hpv
also
downregul
induc
danger
signal
alert
immun
system
prolong
durat
infect
delay
onset
adapt
immun
thu
effect
cmi
requir
clear
control
hpv
infect
effect
vaccineinduc
immun
hpv
consist
cmi
earli
protein
neutral
antibodi
viru
coat
protein
two
current
approv
hpv
vaccin
cervarix
bival
hpv
vaccin
gsk
gardasil
quadrival
hpv
vaccin
merck
highli
protect
hpv
li
vlp
howev
cervarix
gardasil
aah
amorph
aluminum
hydroxyphosph
sulfat
adjuv
vlp
strongli
activ
stromal
dc
inject
site
migrat
dln
may
directli
bind
surfac
apc
immun
cell
migrat
ln
prime
b
cell
accord
recent
studi
girl
age
year
two
dose
cervarix
elicit
superior
antibodi
respons
compar
two
three
dose
gardasil
differ
immunogen
two
vaccin
may
due
differ
type
adjuv
use
enhanc
humor
immun
respons
cmi
trigger
local
transient
cytokin
respons
promot
enhanc
activ
present
abil
apc
significantli
higher
antibodi
titer
induc
mice
immun
vlp
adsorb
onto
aah
compar
vlp
adsorb
onto
aluminum
hydroxid
along
induct
improv
secret
cell
respons
mtb
caus
tb
intracellular
pathogen
abil
surviv
within
hostil
environ
alveolar
macrophag
phagocytos
multipli
uncheck
cell
cell
ctl
cell
nk
cell
activ
macrophag
critic
control
mtb
infect
bacillu
bcg
vaccin
fail
protect
adult
pulmonari
tb
prevent
transmiss
mtb
adolesc
adult
thu
urgent
need
improv
vaccin
tb
one
potenti
vaccin
strategi
mtb
elimin
control
latent
infect
prevent
reactiv
progress
clinic
tb
latent
infect
patient
may
accomplish
incorpor
adjuv
capabl
induc
cell
respons
immunocompet
immunocompromis
individu
mechan
antibodymedi
protect
tb
includ
opson
complement
activ
fc
receptor
engag
current
research
focus
adjuv
act
innat
lymphoid
cell
ilc
nk
cell
nonclass
cell
hlae
cell
present
larg
number
circul
mucosa
although
immun
correl
protect
tb
diseas
valid
yet
vaccin
current
clinic
develop
predominantli
focu
gener
immun
respons
adjuv
miner
salt
saponin
microor
nanoparticl
toxin
deriv
cation
lipid
cpg
dna
adjuv
system
cytokin
test
subunit
vaccin
prepar
either
alon
combin
bcg
primeboost
strategi
strongest
adjuv
tb
unmethyl
mycobacteri
dna
cpg
odn
promot
ctl
activ
product
ligand
present
surfac
mtb
triacyl
diacyl
form
mycobacteri
lipoprotein
secret
bacterium
nlr
respons
intracellular
recognit
mycobacteria
novel
adjuv
includ
dda
tdb
poli
c
gelatin
cpg
odn
mpla
glycopyranosyl
lipid
adjuv
gla
combin
squalen
se
known
glase
also
clinic
test
dda
promot
gener
humor
cellmedi
respons
mtb
induc
strong
immun
mtb
adjuv
subunit
vaccin
induc
protect
immun
enhanc
bcgprime
immun
anim
model
random
doubleblind
phase
trial
candid
tuberculosi
vaccin
e
demonstr
clinic
accept
safeti
profil
confer
protect
activ
pulmonari
tuberculosi
adult
latent
mtb
infect
nanoparticlebas
vaccin
critic
induct
protect
immun
respons
intracellular
pathogen
liposom
adjuv
promot
longlast
memori
cell
respons
human
tb
vaccin
trial
tb
vaccin
stimul
clr
mincl
trigger
signal
cascad
activ
signal
pathway
one
biggest
challeng
vaccin
develop
fact
immunolog
mechan
govern
vaccin
safeti
efficaci
still
larg
unknown
recent
year
system
vaccinolog
emerg
interdisciplinari
approach
reli
highthroughput
omicsbas
techniqu
studi
vaccineinduc
chang
entir
genom
set
transcript
protein
metabolit
variou
tissu
system
vaccinolog
approach
use
elucid
immun
respons
vaccin
yellow
fever
influenza
malaria
smallpox
hiv
addit
system
vaccinolog
approach
identifi
molecular
cellular
immun
signatur
vaccin
bordetella
pertussi
identifi
earli
innat
immun
signatur
correl
antibodi
respons
ebola
vaccin
rvsvzebov
comput
analysi
transcriptom
profil
human
peripher
blood
mononuclear
cell
pbmc
induc
yellow
fever
vaccin
identifi
two
molecular
signatur
eukaryot
translat
initi
factor
alpha
kinas
encod
receptor
bcell
growth
factor
blysbaff
correl
magnitud
cell
respons
correl
magnitud
neutral
antibodi
respons
gene
calreticulin
cjun
glucocorticoid
receptor
also
induc
induct
correl
cell
respons
anoth
studi
young
healthi
adult
intramuscularli
administ
tiv
induc
higher
antibodi
level
plasmablast
compar
intranas
deliv
live
attenu
influenza
vaccin
laiv
induct
distinct
transcript
signatur
enhanc
express
type
ifn
gene
laiv
recipi
tiv
recipi
base
system
vaccinolog
approach
agonist
adjuv
found
potent
enhanc
immunogen
influenza
vaccin
result
improv
antibodi
respons
human
longev
immunoglobulin
respons
post
vaccin
could
predict
abil
adjuv
vaccin
induc
prolifer
antigenspecif
cell
peripher
blood
system
vaccinolog
also
identifi
two
biomark
junb
skelet
muscl
tissu
cell
addit
apc
direct
target
adjuv
action
mice
caproni
et
al
investig
molecular
signatur
induc
differ
tlrdepend
cpg
odn
resiquimod
pam
csk
tlrindepend
alum
adjuv
influenza
subunit
vaccin
establish
innat
immun
correl
adjuvant
use
dna
microarray
mous
model
two
adjuv
pam
csk
increas
overal
antibodi
hai
titer
induc
activ
infiltr
cell
especi
neutrophil
inject
site
suggest
earli
induct
cell
due
emulsionbas
adjuv
predict
subsequ
robust
humor
immun
system
vaccinolog
also
appli
identifi
novel
mechan
induct
respons
adjuv
instanc
adjuv
activ
cystein
proteas
allergen
depend
product
ro
dc
result
induct
ro
oxid
lipid
induc
turn
promot
epitheli
cellmedi
product
thymic
stromal
lymphopoietin
tslp
result
recruit
basophil
ln
induct
immun
respons
mice
gene
associ
memori
b
cell
format
product
antibodi
respons
tank
induc
mice
immun
ovalbumin
ova
adjuv
agonist
studi
candid
malaria
vaccin
rt
human
subject
enhanc
express
gene
involv
immunoproteasom
format
particular
found
respons
confer
protect
parasitemia
induct
immunoproteasom
enhanc
mhc
antigen
present
turn
indirectli
enhanc
antibodi
respons
directli
augment
cell
develop
product
immun
signatur
may
contribut
protect
efficaci
candid
malaria
vaccin
compar
system
analysi
four
vaccin
adjuv
glase
alum
mice
reveal
distinct
molecular
signatur
glase
induc
massiv
chang
transcriptom
profil
whole
blood
dln
correl
increas
cellular
influx
mdc
dln
contrast
limit
transcriptom
chang
induc
adjuv
coexpress
analysi
differenti
express
gene
whole
blood
reveal
glase
induc
transcript
signatur
relat
innat
immun
respons
analysi
also
reveal
modul
enrich
gene
associ
tfh
gcmediat
b
cell
respons
exampl
glase
induc
induc
batf
induc
system
analysi
protect
immun
respons
three
rt
vaccin
subsequ
control
human
malaria
challeng
vaccin
recipi
plasmodiuminfect
mosquito
carri
molecular
signatur
b
cell
plasma
cell
human
pbmc
found
posit
correl
protect
nk
cell
signatur
correl
neg
protect
indic
multipl
mechan
protect
immun
p
falciparum
studi
burni
et
al
differ
adjuv
b
e
alum
oh
induc
common
innat
pathway
respons
improv
adapt
respons
use
model
antigen
hbv
surfac
antigen
hbsag
human
b
e
induc
compar
innat
profil
alum
furthermor
abil
activ
innat
immun
ifnsign
pathway
particular
link
enhanc
adapt
respons
elicit
vaccin
earli
chang
immun
marker
crp
correl
magnitud
adapt
respons
system
vaccinolog
also
identifi
signatur
vaccin
safeti
efficaci
nonspecif
advers
side
effect
observ
vaccin
fail
human
clinic
trial
frequent
associ
overstimul
certain
compon
innat
immun
system
system
vaccinolog
appli
screen
adjuv
help
design
protect
safe
vaccin
correl
protect
establish
number
licens
vaccin
review
tomara
et
al
howev
attempt
identifi
correl
protect
still
ongo
tb
commonli
assum
immun
correl
often
fail
correctli
predict
individu
risk
develop
malaria
hiv
complex
immun
correl
protect
character
multipl
type
immun
respons
found
involv
control
transmiss
vaccin
immun
correl
protect
unknown
system
vaccinolog
approach
use
identifi
signatur
induc
rapidli
vaccin
help
predict
later
immun
outcom
system
vaccinolog
approach
also
help
identifi
vaccin
nonrespond
well
vaccin
highand
lowrespond
innat
adapt
immun
respons
profoundli
influenc
signific
chang
metabol
activ
inflamm
trigger
vaccin
adjuv
result
shift
energi
suppli
lead
metabol
acidosi
impair
oxygen
suppli
turn
result
phenotyp
shift
phenotyp
shift
heavili
affect
metabol
state
individu
lipid
metabol
play
import
role
inflamm
liquid
chromatographymass
spectrometri
lcm
employ
identifi
quantifi
cellor
tissuespecif
metabolit
metabolit
immunecorrel
nucleotid
amino
acid
lipid
fatti
acid
antioxid
may
repres
inflammatori
mediat
andor
biomark
profoundli
influenc
sever
inflammatori
process
cellular
infiltr
activ
signal
pathway
oxid
stress
thu
comprehens
understand
molecular
signatur
induc
adjuv
earli
vaccin
help
predict
later
adapt
immun
respons
human
furthermor
knowledg
also
improv
help
design
nextgener
adjuv
drive
develop
nextgener
vaccin
concert
effort
vaccinologist
clinician
system
biologist
statistician
well
industri
regulatori
author
relationship
adjuv
innat
pathway
receptor
activ
immun
respons
trigger
type
pathogen
ideal
adjuvantmedi
immun
respons
summar
tabl
review
articl
summar
mechan
action
differ
class
adjuv
also
discuss
knowledg
import
context
distinct
diseas
target
knowledg
util
improv
develop
adjuv
vaccin
challeng
pathogen
also
briefli
highlight
import
role
newag
system
vaccinolog
approach
better
understand
adjuv
mode
action
identif
uniqu
cellular
molecular
biomark
adjuvant
import
note
mous
model
offer
flexibl
access
studi
intric
facet
mechan
action
adjuv
respons
immun
adjuv
vaccin
result
anim
studi
often
overlap
result
human
studi
sever
dissimilar
well
instanc
vaccin
mice
induc
cellmedi
humor
immun
respons
observ
human
age
rather
tend
develop
respons
even
human
immun
respons
need
investig
serum
also
dln
lymphoid
organ
prime
site
also
distant
effector
site
holist
reliabl
assess
mechan
action
adjuv
andor
vaccin
made
encompass
possibl
immun
paramet
even
immunolog
correl
recent
identifi
gene
profil
system
vaccinolog
differ
adjuvantsvaccin
defin
popul
level
much
less
individu
level
consider
must
taken
account
design
effect
safe
vaccinesadjuv
recent
advanc
allow
research
conclud
clinicalgrad
adjuv
distinct
immunolog
profil
signatur
use
target
differ
pathogen
base
pathogenspecif
immun
respons
requir
ie
respons
mix
respons
etc
nextgener
adjuv
ration
develop
incorpor
human
vaccin
current
approv
human
adjuv
mostli
induc
antibodi
respons
howev
recent
adjuv
research
led
develop
novel
adjuv
capabl
induc
cmi
especi
requir
malaria
tb
hiv
well
antibodi
respons
new
immunostimulatori
adjuv
immunomodulatori
compound
investig
induc
cmi
high
antibodi
titer
novel
combin
adjuv
test
candid
human
vaccin
promis
result
strong
implic
use
vaccin
challeng
infecti
pathogen
differ
target
popul
potenti
due
activ
multipl
innat
immun
sens
signal
transduct
pathway
combin
adjuv
novel
adjuv
requir
target
emerg
new
pathogen
reemerg
old
pathogen
pathogen
often
complex
hostpathogen
interact
need
better
understand
character
among
newgener
adjuv
sever
proprietari
may
make
difficult
purchas
conduct
independ
parallel
trial
factor
genet
background
preexposur
pathogen
vaccin
antigen
age
nutrit
immunolog
statu
vaccin
recipi
dictat
final
effect
adjuv
vaccin
nevertheless
aid
structur
system
revers
vaccinolog
epitop
predict
technolog
advanc
adjuv
technolog
gradual
progress
toward
person
approach
exponenti
growth
field
adjuv
research
alum
histor
use
licens
adjuv
year
six
new
adjuv
approv
last
year
next
five
year
see
substanti
progress
obtain
licensur
vari
type
adjuv
understand
innat
immun
role
prr
agonist
adjuv
stimul
innat
immun
system
revolution
adjuv
technolog
system
biolog
immens
contribut
develop
effect
potent
adjuv
continu
come
year
correl
adjuvant
immun
signatur
biomark
adjuv
safeti
protect
efficaci
streamlin
adjuv
research
tailormad
adjuv
find
use
distinct
pathogen
specif
target
popul
better
character
adjuv
new
omicsbas
technolog
facilit
licens
new
adjuv
sinc
press
need
develop
vaccin
multitud
virulentemerg
pathogen
need
develop
subunit
vaccin
live
vaccin
henc
adjuv
select
critic
mucos
surfac
prefer
rout
entri
pathogen
therefor
mucos
immun
consid
effect
prevent
mucos
transmit
infect
howev
major
hurdl
develop
mucos
vaccin
lack
safe
effect
mucos
adjuv
due
toxic
issu
specif
need
standard
comprehens
pertin
methodolog
safeti
evalu
enabl
develop
safe
mucos
adjuv
mucos
adjuv
also
requir
promot
bioavail
vaccin
antigen
anoth
requir
develop
mucos
adjuv
optim
target
abil
reduc
undesir
advers
side
effect
sinc
efficaci
toxic
mucos
adjuv
appear
intrins
link
riskbenefit
ratio
need
ascertain
adjuv
attent
must
also
direct
studi
antigenadjuv
interact
instead
irrat
mix
adjuv
vaccin
formul
oilinwat
emuls
promis
adjuv
characterizationanalysi
compon
ad
emuls
prepar
detail
facilit
improv
adjuv
